PIXELWORKS, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PIXELWORKS, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $693.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $690.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $59.68M | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | $16.89M | Mar 8, 2023 |
| FY2022 | Sep 30, 2022 | $17.55M | Mar 8, 2023 |
| FY2022 | Jun 30, 2022 | $19.08M | Mar 8, 2023 |
| FY2022 | Mar 31, 2022 | $16.63M | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | $16.59M | Mar 8, 2023 |
| FY2022 | Sep 30, 2021 | $15.20M | Mar 8, 2023 |
| FY2022 | Jun 30, 2021 | $14.05M | Mar 8, 2023 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $43.21M | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $59.68M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $70.15M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $55.10M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $40.86M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $68.76M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $76.55M | Mar 11, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $20.54M | Mar 13, 2019 |
| FY2018 | Sep 30, 2018 | $21.47M | Mar 13, 2019 |
| FY2018 | Jun 30, 2018 | $19.25M | Mar 13, 2019 |
| FY2018 | Mar 31, 2018 | $15.29M | Mar 13, 2019 |
| FY2018 | Dec 31, 2017 | $18.45M | Mar 13, 2019 |
| FY2018 | Sep 30, 2017 | $18.76M | Mar 13, 2019 |
| FY2018 | Jun 30, 2017 | $20.72M | Mar 13, 2019 |
| FY2018 | Mar 31, 2017 | $22.71M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $15.99M | Mar 14, 2018 |
| FY2017 | Sep 30, 2016 | $13.66M | Mar 14, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $589.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $561.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $25.71M | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | $8.97M | Mar 8, 2023 |
| FY2022 | Sep 30, 2022 | $8.80M | Mar 8, 2023 |
| FY2022 | Jun 30, 2022 | $9.35M | Mar 8, 2023 |
| FY2022 | Mar 31, 2022 | $8.76M | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | $8.87M | Mar 8, 2023 |
| FY2022 | Sep 30, 2021 | $7.99M | Mar 8, 2023 |
| FY2022 | Jun 30, 2021 | $7.11M | Mar 8, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.50M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($28.72M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($26.18M) | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | ($1.93M) | Mar 8, 2023 |
| FY2022 | Sep 30, 2022 | ($4.50M) | Mar 8, 2023 |
| FY2022 | Jun 30, 2022 | ($5.01M) | Mar 8, 2023 |
| FY2022 | Mar 31, 2022 | ($4.59M) | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | ($3.29M) | Mar 8, 2023 |
| FY2022 | Sep 30, 2021 | ($4.07M) | Mar 8, 2023 |
| FY2022 | Jun 30, 2021 | ($4.38M) | Mar 8, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.56M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($12.96M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($28.64M) | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | ($3.01M) | Mar 8, 2023 |
| FY2022 | Sep 30, 2022 | ($4.73M) | Mar 8, 2023 |
| FY2022 | Jun 30, 2022 | ($5.20M) | Mar 8, 2023 |
| FY2022 | Mar 31, 2022 | ($3.88M) | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | ($3.73M) | Mar 8, 2023 |
| FY2022 | Sep 30, 2021 | ($3.90M) | Mar 8, 2023 |
| FY2022 | Jun 30, 2021 | ($4.46M) | Mar 8, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $4.44M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $30.88M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $30.52M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $27.25M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $25.04M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $26.02M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $22.88M | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $21.43M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $19.04M | Mar 13, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.45M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $8.91M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $23.47M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $22.18M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $20.45M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $19.84M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $21.20M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $19.95M | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $20.45M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $13.77M | Mar 13, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.61M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($19.81M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($18.81M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($12.83M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($9.16M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($3.71M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($10.38M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $955.0K | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $12.20M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($1.54M) | Mar 13, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.76M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.83M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.59M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $3.48M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $2.64M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $2.63M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $2.10M | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $2.48M | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | $2.14M | Mar 13, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.26M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $64.10M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $95.97M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $102.32M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $106.60M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $72.04M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $64.66M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $65.34M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $67.54M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $30.86M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.86M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $24.22M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $30.96M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $30.07M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $35.47M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $19.17M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $17.13M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $15.95M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $28.11M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $11.81M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.09M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($10.57M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $12.54M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $32.42M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $40.22M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $52.87M | Mar 9, 2022 |
| FY2021 | Dec 31, 2019 | $47.53M | Mar 9, 2022 |
| FY2020 | Dec 31, 2018 | $49.39M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $43.30M | Mar 11, 2020 |
| FY2019 | Dec 31, 2016 | $22.30M | Mar 11, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $18.41M | Mar 13, 2025 |
| FY2024 | Dec 31, 2023 | $18.41M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $18.41M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $18.41M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $18.41M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $18.41M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $18.41M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $18.41M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($528.38M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($505.88M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($477.16M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($450.99M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($434.96M) | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | ($415.13M) | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | ($388.61M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($379.53M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($379.47M) | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | ($375.26M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.24M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.48M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $47.54M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $56.82M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $61.59M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | $31.26M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | $7.26M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $17.94M | Mar 11, 2020 |
| FY2019 | Dec 31, 2017 | $27.52M | Mar 11, 2020 |
| FY2019 | Dec 31, 2016 | $19.62M | Mar 11, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Mar 13, 2019 |
| FY2018 | Dec 31, 2017 | $6.07M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 14, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 8, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 8, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 8, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (5) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 8, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 8, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 8, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 8, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.34M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 4.98M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 57.13M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 55.11M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 53.37M | Mar 8, 2023 |
| FY2021 | Dec 31, 2020 | 51.08M | Mar 9, 2022 |
| FY2020 | Dec 31, 2019 | 38.43M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 36.94M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | 34.65M | Mar 13, 2019 |
| FY2017 | Dec 31, 2016 | 28.89M | Mar 14, 2018 |